A Phase 3 interventional study of Nintedanib (BIBF1120) and Pemetrexed in Carcinoma, Non-Small-Cell Lung, sponsored by Boehringer Ingelheim. Completed at 167 sites in 32 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-02-02.
Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing nintedanib in Carcinoma, Non-Small-Cell Lung — 1 open to participants now, 2 under way, none of them phase 3. nintedanib · Carcinoma, Non-Small-Cell Lung.
Among the 19 studies testing nintedanib in Carcinoma, Non-Small-Cell Lung, this one is the 2nd largest by enrollment, is one of 2 that started in 2008, is one of 3 in phase 3, and was the 2nd registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →1 of the 19 studies testing nintedanib in Carcinoma, Non-Small-Cell Lung is open now, in 1 country. Recruiting first, the newest first:
China Medical University Hospital · Sites in Taiwan
Ages 20–70
By country, each count listing its studies:
nintedanib: first FDA approval 2014 (OFEV), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 7 · Phase 3 3
First in 2005; this study’s year is marked. 2 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 718 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 16 across the 19 interventional studies. Of the 16 that completed or were terminated, 11 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 19 have an industry lead sponsor. The 8 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
68 studies in Carcinoma, Non-Small-Cell Lung by Boehringer Ingelheim: 3 open now, 5 under way, 1 of them phase 3. Of 60 finished, 53 (88%) have results posted.
Among the 68 studies in Carcinoma, Non-Small-Cell Lung by Boehringer Ingelheim, this one is the 4th largest by enrollment of the 49 interventional ones that give a count, is one of 6 that started in 2008, is one of 14 in phase 3, and was the 8th registered.
Boehringer Ingelheim’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 19 studies testing nintedanib in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Boehringer Ingelheim’s 68 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
The trial will be performed to evaluate if BIBF 1120 in combination with standard pemetrexed therapy is more effective than placebo (inactive capsule) plus standard pemetrexed therapy in patients with stage IIIB, IV or recurrent NSCLC. Safety information about BIBF1120/pemetrexed will be obtained.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
nintedanib (BIBF1120) along with standard therapy of pemetrexed
Drug: Nintedanib (BIBF1120) · Drug: B12 · Drug: dexamethasone (or corticosteroid equivalent) · Drug: Folic Acid · Drug: Pemetrexed
Pemetrexed standard therapy
Drug: pemetrexed · Drug: dexamethasone (or corticosteroid equivalent) · Drug: B12 · Drug: placebo · Drug: Folic Acid
nintedanib (BIBF1120) monotherapy only for patients who discontinue pemetrexed
Drug: Nintedanib (BIBF1120)
pemetrexed monotherapy only for patients who discontinue nintedanib (BIBF1120) or placebo
Drug: Pemetrexed · Drug: B12 · Drug: dexamethasone (or corticosteroid equivalent) · Drug: Folic Acid
placebo monotherapy only for patients who discontinue pemetrexed
Drug: placebo
starting dose of 200 mg bid taken daily except on the day of pemetrexed infusion . The dose can be reduced to 150 bid and then to 100 mg bid.
500 mg/metre squared administered as an intravenous infusion over 10 minutes on Day 1 of each 21 day cycle.
500 mg/metre squared administered as an intravenous infusion over 10 minutes on Day 1 of each 21 day cycle.
1000 ug IM injection starting a week before first pemetrexed infusion and every 9 weeks thereafter until discontinuation of pemetrexed
4 mg PO bid the day before, the day of and the day after each pemetrexed infusion
starting dose of 200 mg bid taken daily except on the day of pemetrexed infusion . The dose can be reduced to 150 bid and then to 100 mg bid.
4 mg PO bid the day before, the day of and the day after each pemetrexed infusion
1000 ug IM injection starting a week before first pemetrexed infusion and every 9 weeks thereafter until discontinuation of pemetrexed
400 ug once daily starting 1-2 weeks prior to the first dose of pemetrexed and continuing for at least 3 weeks after stopping pemetrexed.
1000 ug IM injection starting a week before first pemetrexed infusion and every 9 weeks thereafter until discontinuation of pemetrexed
4 mg PO bid the day before, the day of and the day after each pemetrexed infusion
400 ug once daily starting 1-2 weeks prior to the first dose of pemetrexed and continuing for at least 3 weeks after stopping pemetrexed.
starting dose of 200 mg bid taken daily except on the day of pemetrexed infusion . The dose can be reduced to 150 bid and then to 100 mg bid.
400 ug once daily starting 1-2 weeks prior to the first dose of pemetrexed and continuing for at least 3 weeks after stopping pemetrexed.
starting dose of 200 mg bid taken daily except on the day of pemetrexed infusion . The dose can be reduced to 150 bid and then to 100 mg bid.
500 mg/metre squared administered as an intravenous infusion over 10 minutes on Day 1 of each 21 day cycle.
Progression Free Survival (PFS) as Assessed by Central Independent Review
Progression Free Survival (PFS) as assessed by central independent review according to the modified RECIST (version 1.0) criteria. Progression free survival (PFS) is defined as the duration of time from date of randomisation to date of progression or death (whatever occurs earlier). Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve.
Time frame: From randomisation until cut-off date 9 July 2012
Overall Survival (Key Secondary Endpoint)
Overall Survival (OS) defined as the duration from randomisation to death (irrespective of the reason of death). Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve.
Time frame: From randomisation until data cut-off (15 February 2013), Up to 30 months
Follow-up Analysis of Progression Free Survival (PFS) as Assessed by Central Independent Review
Follow-up analysis was conducted at the time of overall survival analysis. Progression Free Survival (PFS) as assessed by central independent review according to the modified RECIST (version 1.0) criteria. Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve.
Time frame: From randomisation until data cut-off (15 February 2013), Up to 30 months
Follow-up Analysis of Progression Free Survival (PFS) as Assessed by Investigator
Follow-up analysis was conducted at the time of overall survival analysis. Progression Free Survival (PFS) as assessed by investigator according to the modified RECIST (version 1.0) criteria. Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve.
Time frame: From randomisation until data cut-off (15 February 2013), Up to 30 months
Objective Tumor Response
Confirmed objective response is defined as confirmed Complete Response (CR) and Partial Response (PR) and evaluated according to the modified RECIST criteria version 1.0. This endpoint was analysed based on the central independent reviewer as well as the investigator
Time frame: From randomisation until data cut-off (15 February 2013), Up to 30 months
Duration of Confirmed Objective Tumour Response
The duration of objective response is the time from first documented (CR) or (PR) to the time of progression or death and evaluated according to the modified RECIST criteria version 1.0. Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve. This endpoint was analysed based on the central independent reviewer as well as the investigator.
Time frame: From randomisation until data cut-off (15 February 2013), Up to 30 months
Time to Confirmed Objective Tumour Response
Time to confirmed objective response is defined as time from randomisation to the date of first documented (CR) or (PR) and evaluated according to the modified RECIST criteria version 1.0. Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve. This endpoint was analysed based on the central independent reviewer as well as the investigator.
Time frame: From randomisation until data cut-off (15 February 2013), Up to 30 months
Disease Control
Disease control was defined as a best overall response of Complete Response (CR), Partial Response (PR), or Stable Disease (SD) and evaluated according to the modified RECIST criteria version 1.0. This endpoint was analysed based on the central independent reviewer as well as the investigator.
Time frame: From randomisation until data cut-off (15 February 2013), Up to 30 months
Duration of Disease Control
The duration of disease control was defined as the time from randomisation to the date of disease progression or death (which ever occurs first) for patients with disease control. Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve. This endpoint was analysed based on the central independent reviewer as well as the investigator.
Time frame: From randomisation until data cut-off (15 February 2013), Up to 30 months
Change From Baseline in Tumour Size
Percentage change from baseline in tumour size is defined as decrease in the sum of the longest diameter of the target lesion. Presented means are in fact adjusted best means percentage changes generated from ANOVA model adjusted for baseline ECOG PS (0 vs. 1), tumour histology (adenocarcinoma vs. non-adenocarcinoma), brain metastases at baseline (yes vs no) and prior treatment with bevacizumab (yes vs no) This endpoint was analysed based on the central independent reviewer as well as the investigator.
Time frame: From randomisation until data cut-off (15 February 2013), Up to 30 months
Clinical Improvement.
Clinical improvement was defined as the time from randomisation to deterioration in body weight and/or Eastern Cooperative Oncology group performance score (ECOG PS) whichever occurred first. Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve.
Time frame: From randomisation until data cut-off (15 February 2013), Up to 30 months
Quality of Life (QoL)
QoL was measured by standardised questionnaires (EQ-5D, EORTC QLQ-C30, EORTC QLQ-LC13). The EORTC QLQ-C30 comprises of 30 questions, using both multi-item scales and single-item measures. EORTC LC-13 comprises of 13 questions incorporating 1 multi-item scale and a series of single items. The following were the main points of interest: Time to deterioration of cough (QLQ-LC13 question 1), Time to deterioration of dyspnoea (QLQ-LC13, composite of questions 3 to 5), Time to deterioration of pain (QLQ- C30, composite of questions 9 and 19). Time to deterioration of cough, dyspnoea and pain was defined as the time to a 10-point increase from the baseline score. Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve.
Time frame: From randomisation until data cut-off (15 February 2013), Up to 30 months
Dose Normalised Predose Plasma Concentration at Steady State (Cpre,ss,Norm) of Nintedanib and of Its Metabolites BIBF 1202 and BIBF 1202 Glucuronide
Geometric mean of dose normalised predose plasma concentration (Cpre,ss,norm) of nintedanib and of its metabolites BIBF 1202 and BIBF 1202 glucuronide evaluated at steady state based on course 2 and 3. If only one value was available and valid, then this value was used for calculation of Cpre,ss,norm.
Time frame: Before the administration of nintedanib or placebo and between a window of 30 mins to an hour after administration of trial drug during Course 2 and between 1 and 3 hours after administration of trial drug during Course 3
Incidence and Intensity of Adverse Events
Incidence and intensity of adverse events according to the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. The worst CTCAE grade per patient is reported and MedDRA version 15.1 used. Serious signs and symptoms of progressive disease were reported as an adverse event in analysis of this endpoint.
Time frame: From the first drug administration until 28 days after the last drug administration, up to 36 months
| Milestone | Nintedanib Plus Pemetrexed | Placebo Plus Pemetrexed |
|---|---|---|
| Started | 353 | 360 |
| Completed | 7 | 2 |
| Not completed | 346 | 358 |
| Withdrew: Progressive disease (modified recist ) | 217 | 216 |
| Withdrew: Worsening or ae of underlying disease | 18 | 25 |
| Withdrew: Other ae | 38 | 40 |
| Withdrew: Protocol violation | 9 | 4 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Withdrawal by subject | 32 | 29 |
| Withdrew: Not treated | 6 | 3 |
| Withdrew: Reasons other than stated above | 25 | 41 |
Progression Free Survival (PFS) as assessed by central independent review according to the modified RECIST (version 1.0) criteria. Progression free survival (PFS) is defined as the duration of time from date of randomisation to date of progression or death (whatever occurs earlier). Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve.
| months | Nintedanib Plus Pemetrexed | Placebo Plus Pemetrexed |
|---|---|---|
| Progression Free Survival (PFS) as Assessed by Central Independent Review | 4.4 (2.3 to 9.5) | 3.6 (1.4 to 7.5) |
Overall Survival (OS) defined as the duration from randomisation to death (irrespective of the reason of death). Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve.
| months | Nintedanib Plus Pemetrexed | Placebo Plus Pemetrexed |
|---|---|---|
| Overall Survival (Key Secondary Endpoint) | 12.0 (7.0 to 24.2) | 12.7 (5.4 to 24.0) |
Follow-up analysis was conducted at the time of overall survival analysis. Progression Free Survival (PFS) as assessed by central independent review according to the modified RECIST (version 1.0) criteria. Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve.
| Months | Nintedanib Plus Pemetrexed | Placebo Plus Pemetrexed |
|---|---|---|
| Follow-up Analysis of Progression Free Survival (PFS) as Assessed by Central Independent Review | 4.4 (2.3 to 9.5) | 3.4 (1.4 to 7.5) |
Follow-up analysis was conducted at the time of overall survival analysis. Progression Free Survival (PFS) as assessed by investigator according to the modified RECIST (version 1.0) criteria. Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve.
| Months | Nintedanib Plus Pemetrexed | Placebo Plus Pemetrexed |
|---|---|---|
| Follow-up Analysis of Progression Free Survival (PFS) as Assessed by Investigator | 5.3 (2.6 to 9.4) | 4.3 (1.9 to 8.3) |
Confirmed objective response is defined as confirmed Complete Response (CR) and Partial Response (PR) and evaluated according to the modified RECIST criteria version 1.0. This endpoint was analysed based on the central independent reviewer as well as the investigator
| % of participants | Nintedanib Plus Pemetrexed | Placebo Plus Pemetrexed |
|---|---|---|
| Central independent reviewer | 9.1 | 8.3 |
| Investigator assessment | 15.0 | 13.3 |
The duration of objective response is the time from first documented (CR) or (PR) to the time of progression or death and evaluated according to the modified RECIST criteria version 1.0. Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve. This endpoint was analysed based on the central independent reviewer as well as the investigator.
| Months | Nintedanib Plus Pemetrexed | Placebo Plus Pemetrexed |
|---|---|---|
| central independent reviewer (N=32, 30) | 6.9 (5.1 to 11.3) | 4.4 (3.3 to 8.9) |
| Investigator assessment (N=53, 48) | 6.5 (4.4 to 12.7) | 7.2 (4.2 to 16.2) |
Time to confirmed objective response is defined as time from randomisation to the date of first documented (CR) or (PR) and evaluated according to the modified RECIST criteria version 1.0. Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve. This endpoint was analysed based on the central independent reviewer as well as the investigator.
| Months | Nintedanib Plus Pemetrexed | Placebo Plus Pemetrexed |
|---|---|---|
| Central independent review (N=32, 30) | 2.6 (1.4 to 4.0) | 2.7 (1.4 to 4.2) |
| Investigator assessment (N=53, 48) | 2.6 (1.4 to 3.0) | 2.8 (1.4 to 3.1) |
Disease control was defined as a best overall response of Complete Response (CR), Partial Response (PR), or Stable Disease (SD) and evaluated according to the modified RECIST criteria version 1.0. This endpoint was analysed based on the central independent reviewer as well as the investigator.
| % of participants | Nintedanib Plus Pemetrexed | Placebo Plus Pemetrexed |
|---|---|---|
| Central independent review (N=215, 192) | 60.9 | 53.3 |
| Investigator assessment (N=233, 217) | 66.0 | 60.3 |
The duration of disease control was defined as the time from randomisation to the date of disease progression or death (which ever occurs first) for patients with disease control. Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve. This endpoint was analysed based on the central independent reviewer as well as the investigator.
| Months | Nintedanib Plus Pemetrexed | Placebo Plus Pemetrexed |
|---|---|---|
| Central independent review (N=215, 192) | 7.4 (4.3 to 11.2) | 6.8 (4.2 to 12.5) |
| Investigator assessment (N=233, 217) | 6.9 (4.4 to 12.5) | 6.8 (4.4 to 11.1) |
Percentage change from baseline in tumour size is defined as decrease in the sum of the longest diameter of the target lesion. Presented means are in fact adjusted best means percentage changes generated from ANOVA model adjusted for baseline ECOG PS (0 vs. 1), tumour histology (adenocarcinoma vs. non-adenocarcinoma), brain metastases at baseline (yes vs no) and prior treatment with bevacizumab (yes vs no) This endpoint was analysed based on the central independent reviewer as well as the investigator.
| percentage of change in tumor size in mm | Nintedanib Plus Pemetrexed | Placebo Plus Pemetrexed |
|---|---|---|
| Central independent review (N=298, 305) | -10.10 (-12.63 to -7.58) | -7.53 (-10.03 to -5.04) |
| Investigator assessment (N=322, 325) | -15.60 (-18.75 to -12.46) | -11.28 (-14.42 to -8.15) |
Clinical improvement was defined as the time from randomisation to deterioration in body weight and/or Eastern Cooperative Oncology group performance score (ECOG PS) whichever occurred first. Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve.
| Months | Nintedanib Plus Pemetrexed | Placebo Plus Pemetrexed |
|---|---|---|
| Clinical Improvement. | 7.2 (2.8 to 21.9) | 7.5 (1.8 to 24.2) |
QoL was measured by standardised questionnaires (EQ-5D, EORTC QLQ-C30, EORTC QLQ-LC13). The EORTC QLQ-C30 comprises of 30 questions, using both multi-item scales and single-item measures. EORTC LC-13 comprises of 13 questions incorporating 1 multi-item scale and a series of single items. The following were the main points of interest: Time to deterioration of cough (QLQ-LC13 question 1), Time to deterioration of dyspnoea (QLQ-LC13, composite of questions 3 to 5), Time to deterioration of pain (QLQ- C30, composite of questions 9 and 19). Time to deterioration of cough, dyspnoea and pain was defined as the time to a 10-point increase from the baseline score. Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve.
| Months | Nintedanib Plus Pemetrexed | Placebo Plus Pemetrexed |
|---|---|---|
| Time to deterioration of cough | 6.0 (2.2 to 23.6) | 4.3 (1.4 to NA) |
| Time to deterioration of dyspnoea | 2.4 (0.9 to 6.4) | 2.0 (0.8 to 5.7) |
| Time to deterioration of pain | 2.8 (1.2 to 7.0) | 2.7 (1.1 to 8.0) |
Geometric mean of dose normalised predose plasma concentration (Cpre,ss,norm) of nintedanib and of its metabolites BIBF 1202 and BIBF 1202 glucuronide evaluated at steady state based on course 2 and 3. If only one value was available and valid, then this value was used for calculation of Cpre,ss,norm.
| ng/mL/mg | Nintedanib Plus Pemetrexed | Nintedanib 150 mg Bid Plus Pemetrexed |
|---|---|---|
| Nintedanib BIBF 1120 (N=188, 39) | 0.0883 ± 66.4 | 0.103 ± 72.9 |
| Nintedanib BIBF 1202 (N=188, 40) | 0.131 ± 123 | 0.151 ± 125 |
| Nintedanib BIBF 1202 glucuronide (N=184, 39) | 1.40 ± 169 | 1.72 ± 185 |
Incidence and intensity of adverse events according to the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. The worst CTCAE grade per patient is reported and MedDRA version 15.1 used. Serious signs and symptoms of progressive disease were reported as an adverse event in analysis of this endpoint.
| % of participants | Nintedanib Plus Pemetrexed | Placebo Plus Pemetrexed |
|---|---|---|
| CTCAE grade 1 | 4.9 | 9.2 |
| CTCAE grade 2 | 22.2 | 30.5 |
| CTCAE grade 3 | 46.1 | 34.5 |
| CTCAE grade 4 | 12.4 | 7.8 |
| CTCAE grade 5 | 9.8 | 12.0 |
Collected over From the first drug administration until 28 days after the last drug administration, up to 36 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Nintedanib Plus Pemetrexed | — | 104/347 (30%) | 320/347 (92.2%) |
| Placebo Plus Pemetrexed | — | 117/357 (32.8%) | 312/357 (87.4%) |
| Event | Nintedanib Plus Pemetrexed | Placebo Plus Pemetrexed |
|---|---|---|
| PneumoniaInfections and infestations | 11/347 | 16/357 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 9/347 | 11/357 |
| AnaemiaBlood and lymphatic system disorders | 5/347 | 8/357 |
| Febrile neutropeniaBlood and lymphatic system disorders | 7/347 | 3/357 |
| DehydrationMetabolism and nutrition disorders | 6/347 | 4/357 |
| VomitingGastrointestinal disorders | 3/347 | 6/357 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 5/347 | 6/357 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 5/347 | 3/357 |
| General physical health deteriorationGeneral disorders | 4/347 | 3/357 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 4/347 | 1/357 |
| Event | Nintedanib Plus Pemetrexed | Placebo Plus Pemetrexed |
|---|---|---|
| Alanine aminotransferase increasedInvestigations | 149/347 | 87/357 |
| Aspartate aminotransferase increasedInvestigations | 129/347 | 68/357 |
| NauseaGastrointestinal disorders | 126/347 | 118/357 |
| FatigueGeneral disorders | 116/347 | 127/357 |
| DiarrhoeaGastrointestinal disorders | 118/347 | 54/357 |
| Decreased appetiteMetabolism and nutrition disorders | 97/347 | 89/357 |
| VomitingGastrointestinal disorders | 84/347 | 68/357 |
| Neutrophil count decreasedInvestigations | 74/347 | 47/357 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 45/347 | 70/357 |
| ConstipationGastrointestinal disorders | 50/347 | 65/357 |
Randomised set uncut (RS): all patients who were randomised whether patients had received study treatment or not. Patients were allocated to the treatment groups as randomised, regardless of the actual medication taken.
| Age, Continuous(years) | Nintedanib Plus Pemetrexed | Placebo Plus Pemetrexed | Total |
|---|---|---|---|
| Mean | 59.2 ± 10.3 | 58.7 ± 10.9 | 59.0 ± 10.6 |
| Gender(Participants) | Nintedanib Plus Pemetrexed | Placebo Plus Pemetrexed | Total |
|---|---|---|---|
| Female | 158 | 152 | 310 |
| Male | 195 | 208 | 403 |
Showing the first 100 of 167 sites across 32 countries. Choose a country and city above to see the rest.
The record gives a start of Dec 2008, a primary completion of Jun 2011 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2014, 3 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Nintedanib · B12
Carcinoma, Non-Small-Cell Lung →